Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1363 views | HTML 3907 views | ?
Karin Hoppe-Seyler1, Anja Honegger1, Felicitas Bossler1, Jasmin Sponagel1, Julia Bulkescher1, Claudia Lohrey1 and Felix Hoppe-Seyler1
1Molecular Therapy of Virus-Associated Cancers (F065), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Felix Hoppe-Seyler, email: [email protected]
Keywords: human papillomavirus; cervical cancer; hexokinase 2
Received: August 23, 2017 Accepted: October 27, 2017 Published: November 15, 2017
Oncogenic types of human papillomaviruses (HPVs) are major human carcinogens. Cancer cells typically exhibit metabolic alterations which support their malignant growth. These include an enhanced rate of aerobic glycolysis (‘Warburg effect’) which in cancer cells is often linked to an increased expression of the rate-limiting glycolytic enzyme Hexokinase 2 (HK2). Intriguingly, recent studies indicate that the HPV E6/E7 oncogenes cause the metabolic reprogramming in HPV-positive cancer cells by directly upregulating HK2 expression. Notably, however, these results were obtained upon ectopic overexpression of E6/E7. Here, we investigated whether HK2 levels are affected by the endogenous E6/E7 amounts present in HPV-positive cancer cell lines. RNA interference analyses reveal that the sustained E6/E7 expression is critical to maintain HK2 expression levels in HeLa cells. Mechanistically, this effect is linked to the E6/E7-dependent upregulation of HK2-stimulatory MYC expression and the E6/E7-induced downregulation of the HK2-inhibitory micro(mi)RNA miR-143-3p. Importantly, however, a stimulatory effect of E6/E7 on HK2 expression was observed only in HeLa among a panel of 8 different HPV-positive cervical and head and neck cancer cell lines. Thus, whereas these results support the notion that E6/E7 can increase HK2 expression, they argue against the concept that the viral oncogenes, at endogenous expression levels, commonly induce the metabolic switch of HPV-positive cancer cells towards aerobic glycolysis by directly or indirectly stimulating HK2 expression.
Almost 5% of the total human cancer incidence is closely linked to infections by oncogenic types of human papillomaviruses (HPVs), such as HPV16 and HPV18 [1, 2]. These malignancies include common cancers in the oropharynx and in the anogenital region. The most prevalent HPV-induced malignancy is cervical cancer, which is virtually always caused by oncogenic HPVs and accounts for over 500,000 new cancer cases and over 250,000 cancer deaths worldwide every year . Within cervical cancer cells, the viral DNA is often integrated into the host cell chromosomes . These HPV sequences regularly express the viral E6/E7 oncogenes which are considered to be crucial for both the induction of HPV-linked malignant cell transformation and the maintenance of the oncogenic phenotype of HPV-positive cancer cells [1, 5, 6].
Cancer cells typically exhibit metabolic alterations which support their malignant growth by promoting cellular proliferation and cell survival . During metabolic reprogramming, cancer cells commonly increase the rate of aerobic glycolysis (‘Warburg effect’) for the generation of energy (ATP) and intermediates for tumor cell growth (e.g. nucleic acid precursors, lipids) . A key regulatory and rate-limiting role in this process is played by the glycolytic enzyme Hexokinase 2 (HK2) which is expressed at only very low concentrations in most normal tissues but often at elevated levels in cancers [9, 10]. Thus, it is of high interest to identify cellular factors that stimulate HK2 expression and thereby induce the metabolic switch towards aerobic glycolysis in cancer cells.
Interestingly, recent studies report a direct link between the activity of the HPV oncogenes and HK2 expression. Specifically, it was shown that ectopic HPV16 E6/E7 overexpression increases HK2 levels and, consequently, glycolysis in mouse embryonal fibroblasts (MEFs) in a MYC (c-myc)-dependent manner . Along this line, ectopic overexpression of E7, but not of E6, also stimulated HK2 expression in cervical cancer cell lines and was linked to an increased proliferation rate and to radioresistance . Based on these results, it was postulated that the E6/E7 oncogenes reprogram HPV-positive cancer cells towards glycolysis through a direct activation of HK2 expression [11, 12]. This is of high interest for the field, indicating a novel critical activity of the HPV oncogenes for the maintenance of the transformed phenotype of their host cell. Notably, however, E6/E7 expression levels from the authentic viral promoter are tightly controlled in HPV-positive cancer cells [6, 13] and it is unclear to which extent the observed crosstalk between the viral oncogenes and HK2 expression might be influenced by the intracellular E6/E7 amounts that are generated by the ectopic overexpression from the heterologous promoters used in the studies referenced above.
To address this issue, we here examined a panel of HPV16- or HPV18-positive cervical cancer and head and neck cancer (HNSCC) cell lines which allow to functionally analyze the relation between endogenous E6/E7 and HK2 expression in the background of HPV-transformed cells. In support of the potential of E6/E7 to stimulate HK2 expression, we found that E6/E7 silencing leads to a strong reduction of HK2 mRNA and protein expression in HeLa cells. Mechanistically, this is mediated, at least in part, by the downregulation of HK2-stimulatory MYC expression and by the upregulation of the HK2-inhibitory micro(mi)RNA miR-143-3p, following E6/E7 repression. Notably, however, among 8 tested HPV-positive cancer cell lines, E6/E7 silencing was linked to a decrease of HK2 levels only in HeLa cells. Thus, whereas endogenous E6/E7 can contribute to the maintenance of HK2 levels in HPV-positive cancer cell lines, this appears to be a rare scenario and questions the emerging concept that HK2 levels in HPV-positive cancer cells are commonly dependent on the HPV oncogenes.
Relation between HPV E6/E7 and HK2 expression in HPV-positive cancer cell lines
HPV16-positive SiHa, CaSki and MRI-H-196 and HPV18-positive HeLa and SW756 cervical cancer cells as well as HPV16-positive UDSCC2, SCC152 and SCC154 HNSCC cells were transfected with siRNAs that target all three transcript classes coding for HPV16 E6/E7 or HPV18 E6/E7, respectively . Notably, although viral E6/E7 expression was efficiently reduced by RNA interference (RNAi) in all cell lines, only HeLa cells exhibited a concomitant downregulation of HK2 protein levels (Figure 1A, Supplementary Figure 1). In all other cell lines, HK2 expression remained unchanged (e.g. in CaSki cells) or marginally increased (e.g. in SiHa cells).
Figure 1: HK2 and MYC levels in HPV-positive cancer cells upon silencing of endogenous E6/E7 expression. (A) Immunoblot analyses. HPV E6/E7 expression was silenced by RNAi in HPV18-positive (HeLa, SW756) and HPV16-positive (CaSki, SiHa, MRIH196) cervical cancer cells and in HPV16-positive (UDSCC2, SCC152, SCC154) HNSCC cells. E7, E6, HK2 and MYC protein levels were determined. siContr-1, control siRNA. β-Actin, loading control. (B) Immunoblot analyses. Endogenous HPV18 E6 or E6/E7 expression were silenced in HeLa cells by RNAi. Indicated are E7, E6 and HK2 protein levels. siContr-1, control siRNA. β-Actin, loading control. (C) Quantitative analyses of HK2 protein levels upon E6/E7 silencing. Data is derived from multiple independent experiments in HeLa (n = 5), SiHa (n = 11) and CaSki (n = 6) cells and was quantified by densitometric scanning. For each cell line, relative protein levels are indicated (log2 display), compared with control-siRNA-transfected cells. Left panel: E7 protein expression, right panel: HK2 protein expression levels. Standard deviations are depicted. (D) Accompanying qRT-PCR analyses of HK2 transcript levels (right panel) upon E6/E7 silencing (left panel). Values (log2 display) are derived from multiple independent experiments in HeLa (n = 5), SiHa (n = 11) and CaSki (n = 6) cells, and are indicated relative to control-siRNA-transfected cells.
Next, we tested whether HK2 expression levels in HeLa cells depend on endogenous HPV E6 or E7 expression. The E6/E7 genes are transcribed in HeLa cells from integrated HPV copies, giving rise to three different transcript classes 1–3 [15, 16]. The specific targeting of class 1 transcripts by RNAi (si18E6) leads to E6 repression  (Figure 1B) whereas targeting of mRNA sequences which are common to all three transcript classes (si18E6/E7) leads to the repression of both E6 and E7 (Figure 1B). Despite many efforts, we thus far are unable to selectively silence endogenous E7 expression by RNAi. Clearly, however, whereas E6-specific RNAi leads to a strong downregulation of E6 expression without affecting E7, the HK2 amounts in HeLa cells remained unchanged (Figure 1B). In contrast, combined E6/E7 silencing results in a strong downregulation of HK2 levels. This indicates that the activation of HK2 expression in HeLa cells is linked to the continuous expression of E7, but not of E6, in line with the results of E6 and E7 overexpression in cervical cancer cells .
Based on the results of the immunoblot analyses (Figure 1A), we chose HeLa, CaSki and SiHa cells for detailed quantitative analyses of HK2 expression. Investigating HK2 protein levels upon E6/E7 silencing in 5–11 independent experiments per cell line revealed a strong reduction in HeLa, whereas HK2 expression in SiHa cells slightly increased and remained largely unaffected in CaSki cells (Figure 1C). Accompanying qRT-PCR analyses reveal a corresponding regulation at the HK2 mRNA level (Figure 1D).
Collectively, these results indicate that HK2 protein and mRNA expression are reduced upon E6/E7 repression only in HeLa cells and not in any of the other investigated HPV-positive cervical cancer and HNSCC cell lines.
The E6/E7-dependent regulation of HK2 expression in HeLa cells is linked to MYC
In line with previous findings at the mRNA level , we observed that E6/E7 repression results in strongly decreased MYC protein expression levels in HeLa cells (Figure 1A). However, like the downregulation of HK2 expression upon E6/E7 silencing, the profound MYC downregulation was again specific for HeLa cells and was not detected in any of the other investigated HPV-positive cancer cell lines (Figure 1A). Note that the antibody used for MYC detection yields a double band which likely represents phosphorylated and unphosphorylated forms of the protein [18, 19]. Both bands are strongly reduced upon intracellular expression of three different short hairpin (sh)RNAs targeting the MYC mRNA, corroborating that the signals are derived from MYC (Figure 2A).
Figure 2: HK2 levels in HeLa cells depend on E6/E7-linked stimulation of MYC expression. (A) Immunoblot analysis of HeLa cells transfected with three different shRNAs (shMYC-1, shMYC-2, shMYC-3) to block MYC expression. Protein levels of MYC and HK2 are indicated. shContr-1, HeLa cells transfected with control shRNA; β-Actin, loading control. (B) Immunoblot analysis of HeLa cells transfected with sh18E6/E7 or shContr-1. In addition, cells were concomitantly transfected with a MYC expression vector (+) or the corresponding control vector (–), i.e. the expression vector devoid of MYC sequences. Indicated are HK2, MYC and HPV18 E6 and E7 protein levels. β-Actin, loading control.
To examine whether the correlation between MYC and HK2 levels in HeLa cells is functionally linked, we tested whether MYC silencing leads to the downregulation of HK2 expression. As shown in Figure 2A, shRNA-mediated inhibition of MYC expression resulted in decreased HK2 protein levels. This indicates that the E6/E7-dependent HK2 expression in HeLa cells is maintained, at least in part, via the E6/E7-induced expression of MYC. In support of this conclusion, the downregulation of HK2 expression upon E6/E7 silencing in HeLa cells can be counteracted by ectopic expression of MYC (Figure 2B).
The E6/E7-mediated regulation of HK2 expression in HeLa cells is linked to miR-143-3p
In a deep sequencing analysis of E6/E7-regulated miRNAs, it was found that–among the most abundant intracellular miRNA species (>1000 reads per million)–miR-143-3p shows the highest upregulation following endogenous E6/E7 repression in HeLa cells . This miRNA is well defined as a negative regulator of HK2 expression [20–23]. Notably, and in contrast to the situation in HeLa cells, miR-143-3p was not upregulated upon E6/E7 repression in CaSki or in SiHa cells (Figure 3A). Thus, the ability of HeLa cells to repress HK2 expression upon E6/E7 silencing correlates with the induction of miR-143-3p, raising the possibility that this miRNA directly contributes to the regulation of HK2 expression by E6/E7.
Figure 3: HK2 levels in HeLa cells depend on E6/E7-linked repression of miR-143-3p expression. (A) Analyses of miR-143-3p levels in HeLa, SiHa and CaSki cells upon silencing of viral E6/E7 expression by RNAi. Indicated are changes of relative miRNA levels upon transfection of E6/E7-targeting siRNAs (siE6/E7; i.e. si18E6/E7 in HeLa or si16E6/E7 in SiHa and CaSki cells) compared with control-siRNA (siContr-1)-transfected cells (log2 display). Data is derived from 3 (HeLa), 4 (SiHa) and 4 (CaSki) independent analyses, respectively. Standard deviations are depicted. (B) Immunoblot analysis of HK2 and HPV18 E7 protein levels in HeLa cells following transfection with siContr-1, with a synthetic miR-143-3p mimic or with si18E6/E7, respectively. Mock control, treatment with the transfection agent only. (C) Immunoblot analysis of HeLa cells transfected with si18E6/E7 or control siRNA siContr-1. In addition, cells were co-transfected with miR-143-3p inhib. or inhib. control, as indicated. HK2 and HPV18 E7 protein levels are illustrated. β-Actin, loading control.
To investigate this question, we treated HeLa cells with chemically synthesized miR-143-3p mimics and inhibitors. Introduction of a miR-143-3p mimic did not affect HPV E7 protein levels but resulted in a reduction of HK2 protein amounts (Figure 3B), indicating that miR-143-3p is able to repress HK2 expression in HeLa cells.
Next, we addressed the question whether the miR-143-3p induction upon E6/E7 silencing (Figure 3A) is involved in the concomitant downregulation of HK2 expression in HeLa cells. In this case, the inhibition of miR-143-3p function should counteract the HK2 repression that is observed upon E6/E7 silencing. Thus, we blocked E6/E7 expression by siRNA and simultaneously introduced either a control miRNA inhibitor (‘inhib. control’) or a specific miR-143-3p inhibitor. We found that the miR-143-3p inhibitor counteracted HK2 repression in response to E6/E7 silencing (Figure 3C). Collectively, these data show that HK2 repression upon E6/E7 silencing is linked to the induction of the HK2-targeting miR-143-3p, indicating that the downregulation of this miRNA species by E6/E7 contributes to the elevation of HK2 expression in HeLa cells.
HPV-positive cervical cancer cells are considered to be ‘oncogene addicted’  in that their growth is dependent on the continuous expression of the viral E6/E7 oncogenes [1, 5, 6]. The definition of the cellular targets attacked by the viral oncogenes is therefore of high interest in order to decipher the critical molecular mechanisms of HPV-linked malignant cell transformation and to identify new pathways for therapeutic intervention .
Studies reporting increased HK2 expression and activity in cervical cancers compared to normal cervical epithelium date back to the 1970s [25, 26]. In recent immunohistochemistry analyses, normal cervical tissues exhibited little or no HK2 signals whereas approximately 60% of the cervical cancer specimens (n = 197) stained positive for HK2 . This scenario could also be of clinical relevance since increased HK2 expression is a negative prognostic marker for several solid tumors . These include cervical cancer [11, 12, 27] where high HK2 levels are also linked to radiation resistance [12, 28], in line with the concept that increased glycolysis can confer resistance of cancer cells to radiotherapy . As a consequence of its tumor-promoting potential and elevated expression in many tumors, HK2 is discussed to serve as a novel target for cancer therapy .
It is assumed that cancer cells benefit from increased HK2 expression by various means. HK2 stimulates aerobic glycolysis which provides energy and the necessary building blocks for tumor cell growth . In addition, HK2 plays an important role for glutamine-derived carbon utilization in anaplerosis, supplying intermediates for the TCA (tricarboxylic acid) cycle , and contributes to the maintenance of cellular energy homeostasis by facilitating autophagy in response to glucose deprivation . Moreover, HK2 binds to the pore-forming outer mitochondrial membrane protein VDAC (voltage dependent anion channel) . This interaction is important for the cellular ATP supply by coupling glycolysis to oxidative phosphorylation . Furthermore, the HK2/VDAC interaction can block apoptosis via several mechanisms [10, 35], including by interfering with the formation of the mitochondrial permeability transition pore  and by inhibiting pro-apoptotic proteins that target the outer mitochondrial membrane . Thus, the recent reports demonstrating the potential of E6/E7 to stimulate expression of HK2 [11, 12] are intriguing, since they provide a direct connection between the HPV oncogenes and the expression of a key cellular enzyme responsible for the metabolic reprogramming and apoptotic resistance of cancer cells, which is linked to increased oncogenicity and decreased therapeutic sensitivity in the clinic.
However, the studies reporting the stimulation of HK2 expression by the HPV oncogenes were based on ectopic E6/E7 overexpression [11, 12] and it is not clear to which extent the E6/E7 concentrations generated in these experiments reflect the biological effects of the endogenous E6/E7 amounts generated in HPV-positive cancer cells. Here, we found that the endogenous HPV oncogene expression is critical for maintaining HK2 expression in HeLa cells, since E6/E7 silencing results in a strong downregulation of both HK2 transcript and protein levels. Mechanistically, this response is linked to at least two processes. First, E6/E7 repression in HeLa cells results in a reduction of MYC transcript  and MYC protein levels (Figure 1A), thereby downregulating a known activator of HK2 transcription . This mechanism also appears to contribute to the upregulation of HK2 expression upon ectopic overexpression of E6/E7 in MEFs which is linked to MYC . Further, it recently has been reported that HPV E6 can stabilize the MYC protein  and thus E6/E7 repression could additionally lead to an increased MYC protein turnover. Second, E6/E7 repression results in a significant induction of miR-143-3p , indicating that E6/E7 downregulates the levels of this abundant HK2 inhibitory miRNA. Both processes seem to contribute to the stimulation of HK2 expression by E6/E7 in HeLa cells, since HK2 repression upon E6/E7 silencing could be counteracted by the ectopic expression of MYC as well as by miR-143-3p inhibition. Importantly, however, HK2 repression upon silencing endogenous E6/E7 expression was only observed in HeLa cells among 8 different tested HPV-positive cervical cancer and HNSCC cell lines.
Another difference between the overexpression studies referenced above and our study is the fact that cervical cancer cells react with a proliferative stop and rapid induction of senescence following silencing of endogenous E6/E7 expression . As was shown for HeLa and SiHa cells under the experimental conditions used of the present study (harvesting the cells 72 h after transfection of E6/E7-inhibitory siRNAs), the cells reconstitute p53 and pRb signaling, are growth arrested, and will be senescent or senescing . Yet, HK2 expression is strongly downregulated by E6/E7 silencing only in HeLa cells, suggesting that the reconstitution of the p53 and pRb pathways or the growth-arrested/senescent phenotype of the cells do not explain the differential crosstalk between E6/E7 and HK2 in HeLa and SiHa cells.
The lack of correlation between E6/E7 and HK2 expression in the context of HPV-positive cancer cells, however, does not preclude that E6/E7 may stimulate HK2 expression at some step of the life cycle of HPVs which is closely linked to the differentiation status of the infected keratinocyte . Notably, other viruses also possess the potential to stimulate HK2 expression, including EBV (Epstein-Barr virus) , KSHV (Kaposi’s sarcoma-associated virus) , HCV (hepatitis C virus) , DENV (Dengue virus)  or Ad5 (adenovirus 5) . Similar as observed for endogenous HPV E6/E7 expression in HeLa cells (this study) or for ectopically expressed E6/E7 in MEFs , the stimulation of HK2 expression by Ad5 E4ORF1 is linked to the activation of MYC . It is conceivable that viruses profit from stimulating HK2 expression in their life cycle, since enhanced glycolysis provides an increased nucleotide supply necessary for optimal viral replication [44, 45].
The findings of this study also build a basis for future investigations. Firstly, since HeLa cells are derived from an adenocarcinoma whereas all other investigated cell lines stem from squamous cell carcinomas, the question emerges whether the histological background of HPV-positive cancer cells may influence the crosstalk between E6/E7 and HK2. Secondly, MYC is a master regulator of many metabolic processes, including glycolysis, glutaminolysis, nucleotide production or lipid synthesis . The dependency of MYC expression levels on E6/E7 may provide a functional link between the viral oncogenes and these important cancer-linked metabolic circuits in HeLa cells, an issue that deserves further exploration.
Collectively, our results support the notion that the HPV E6/E7 oncogenes possess the potential to induce HK2 expression. However, HK2 levels in most HPV-positive cancer cell lines are not maintained by the viral oncogenes and the anti-tumorigenic effects observed upon E6/E7 inhibition in these cells are likely not due to decreased HK2 expression. These findings put into question the emerging concept that the E6/E7 oncogenes commonly maintain the metabolic switch of HPV-positive cancer cells towards aerobic glycolysis by directly or indirectly increasing HK2 expression.
MATERIALS AND METHODS
Cell culture, transfections and treatment conditions
HPV18- (HeLa, SW756), HPV16-positive (SiHa, CaSki, MRI-H-196) cervical cancer cells (obtained from the Tumor Bank of the German Cancer Research Center, Heidelberg or from the American Tissue Culture Collection, ATCC) and HPV16-positive HNSCC UDSCC2  and SCC154  cells were cultured in DMEM. HPV16-positive HNSCC SCC152 cells  were cultured in MEM containing non-essential amino acids. Media were supplemented with 10% FCS (Gibco, Life Technologies, Carlsbad, CA, USA), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich, Saint Louis, MO, USA). The identity of each cell line was verified by multiplex human cell line authentication. Authenticated cells were frozen in aliquots and cells were used in experiments for a maximum of 4 weeks after thawing. Plasmids were transfected by calcium phosphate co-precipitation as described . Expression vector pcDNA3-cmyc was created by Dr. Wafik El-Deiry and obtained from www.addgene.org (plasmid # 16011), pcDNA3.1 vector (Life Technologies) devoid of MYC-coding sequences was used as negative control.
siRNAs were either chemically synthesized (Ambion, Life Technologies, Carlsbad, CA, USA) or expressed as shRNAs from vector pSUPER, as previously described . The si/shRNA target sequences were as follows: HPV18 E6/E7-1 5ʹ-CCACAACGU CACACAAUGU-3ʹ; HPV18 E6/E7-2 5ʹ-CAGAGAAA CACAAGUAUAA-3ʹ; HPV18 E6/E7-3 5ʹ-UCCAG CAGCUGUUUCUGAA-3ʹ, HPV16 E6/E7-1 5ʹ-CCGGA CAGAGCCCAUUACA-3ʹ; HPV16 E6/E7-2 5ʹ-CACCU ACAUUGCAUGAAUA-3ʹ; HPV16 E6/E7-3 5ʹ- CAAC UGAUCUCUACUGUUA-3ʹ; HPV18 E6-1 5′-GACAU UAUUCAGACUCTGU-3′, HPV18 E6-2 5′-CAGAC UCUGUGUAUGGAGA-3′, HPV18 E6-3 5′-CUCUGU GUAUGGAGACACA-3′; MYC-1 5ʹ-CGATGTTGTT TCTGTGGAA-3ʹ; MYC-2 5ʹ-GCTTGTACCTGCAGG ATCT-3ʹ; MYC-3 5ʹ-GATGAGGAAGAAATCGATG-3ʹ. Control si/shRNA “Contr-1”, 5ʹ-CAGUCGCGUUUGC GACUGG-3ʹ, contains at least four mismatches to all known human genes.
Synthetic siRNAs (Ambion, Life Technologies) and miR-143-3p mimic (Qiagen, Hilden, Germany) were transfected with DharmaFECT I (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions, to reach a final concentration of 10 nM. For silencing of HPV18 or HPV16 E6/E7 oncogene expression, three different si/shRNAs, which each target all three E6/E7-encoding transcript classes, were pooled at equimolar concentrations to minimize potential off-target effects [14, 40] (referred to in the text as “si/sh18E6/E7” or “si/sh16E6/E7”, respectively). Likewise, HPV18 E6 was silenced by using a pool of equimolar concentrations of three different siRNAs targeting the E6-encoding transcript class 1  (referred to in the text as si18E6). miR-143-3p Inhibitor (Qiagen) and the miScript Inhibitor Negative Control (Qiagen) were transfected with DharmaFECT I (Thermo Fisher Scientific) to reach a final concentration of 100 nM.
In all experiments, cells were harvested for further analyses 72 h after transfection.
RNA extraction and quantitative reverse transcription-PCR (qRT-PCR)
RNA was isolated with the Pure Link RNA Mini Kit (Ambion, Life Technologies) or, for miRNA detection, with the miRNeasy Mini Kit (Qiagen) following the manufacturer’s protocols. Reverse transcription of 1 μg RNA was carried out with the Proto-Script First Strand cDNA Synthesis Kit (New England Biolabs, Ipswich, MA, USA) or with the miScript II Reverse Transcription Kit (Qiagen) for mRNA or miRNA detection, respectively. qRT-PCR reactions were performed on a 7300 Real-Time PCR System Detector (Applied Biosystems) with the SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) for mRNA and with the miScript SYBR Green PCR Kit (Qiagen) for miRNA analysis.
The forward (fwd) and reverse (rev) primer sequences (Eurofins MWG, Ebersberg, Germany) were as follows: HPV18 E6/E7 fwd 5ʹ-ATGCATGGAC CTAAGGCAAC-3ʹ, HPV18 E6/E7 rev 5ʹ-AGGTCGTCT GCTGAGCTTTC-3ʹ, HPV16 E6/E7 fwd 5ʹ-CAATGTTTC AGGACCCACAGG-3ʹ, HPV16 E6/E7 rev 5ʹ-CTCACGT CGCAGTAACTGTTG-3ʹ; HK2 fwd 5ʹ-GCCCACCTA CGTGTGTGCTA-3ʹ, HK2 rev 5ʹ-CACCCCACTTCC CATTCCGA-3ʹ; ACTB fwd 5ʹ-AGACAGTATACCCCA TGCTGCAT-3ʹ, ACTB rev 5ʹ-TCCAATGTGTCTCC ATACACAGA-3ʹ; 18S RNA fwd 5ʹ-CATGGCCGTT CTTAGTTGGT-3ʹ, 18S RNA rev 5ʹ-ATGCCAGAGT CTCGTTCGTT-3ʹ. Cycling conditions have been previously described . The sizes of the PCR products were initially analyzed by agarose gel electrophoresis and subsequently checked by melting point analysis after each reaction using the 7300 System SDS Software (Applied Biosystems). Cycle thresholds (Ct) were normalized to the Cts of ACTB or 18S RNA using the comparative Ct (2–ΔΔCt) method . Fold enrichments were calculated as compared to the values from the siContr-1 treated samples.
For miRNA analysis samples were run in triplicate for each experiment. Data were analyzed using the comparative Ct (2–ΔΔCt) method  with the small nuclear RNA RNU6-2 as endogenous control and siContr-1-treated samples as reference. The following miScript Primer Assays (Qiagen) were applied: Hs_miR-143_1 (hsamiR-143-3p), Hs_RNU6–2_1 (RNU6-2).
Cellular protein was prepared and analyzed by immunoblotting as described . The following primary antibodies were used: anti-β-actin (A2228; Sigma-Aldrich); anti-HPV18 E7 (E7C); anti-HPV16 E7 (NM2, kind gift of Dr. Martin Müller, German Cancer Research Center, Heidelberg, Germany); anti-HPV18 E6 (AVC 399) and anti-HPV16 E6 (AVC 843) (kind gift from Dr. Johannes Schweizer, Arbor Vita Corporation, Fremont, CA, USA); anti-HK2 (sc-6521; Santa Cruz); anti-c-myc (51-1485GR; BD Pharmingen, San Diego, Ca, USA). Experiments analyzed by immunoblot were repeated at least thrice with consistent results.
Images were monitored using Fusion SL Gel Detection System (Vilber Lourmat, Marne-la-Valleé, France). Band densities were determined by BioID image analysis software (Vilber Lourmat), relative to the respective loading controls.
Fold enrichment data was analyzed following logarithmic transformation. Statistical significance of the data was evaluated by the paired Student’s t-test using the Sigma Plot software (Systat Software Inc., San Jose, CA, USA). P-values of p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***) were considered statistically significant.
Karin Hoppe-Seyler, Anja Honegger and Felix Hoppe-Seyler designed research, Karin Hoppe-Seyler, Anja Honegger, Jasmin Sponagel, Julia Bulkescher and Claudia Lohrey performed experiments, Karin Hoppe-Seyler, Anja Honegger, Felicitas Bossler and Felix Hoppe-Seyler analyzed data, Felix Hoppe-Seyler wrote the paper.
We thank Prof. Thomas Hoffmann, University of Ulm, Germany for UDSCC2, and Prof. Susanne M. Gollin, University of Pittsburgh, U.S.A. for SCC152 and SCC154 cells.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2:342–350.
2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141:664–670.
3. American Cancer Society. Cancer facts and Figures 2015. American Cancer Society, Atlanta, GA, USA. 2015.
4. McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 2017; 13:e1006211. https://doi.org/10.1371/journal.ppat.1006211.
5. Howley PM, Schiller JT, Lowy DR. Papillomaviruses. Fields Virology 6th ed, eds Knipe DM, Howley PM (Philadelphia, PA: Lippincott, Williams and Wilkins). 2013; 1662–1703.
6. Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2017 Aug 17. http://dx.doi.org/10.1016/j.tim.2017.07.007. [Epub ahead of print].
7. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23:27–47.
8. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016; 41:211–218.
9. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003; 206:2049–2057.
10. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006; 25:4777–4786.
11. Zeng Q, Chen J, Li Y, Werle KD, Zhao RX, Quan CS, Wang YS, Zhai YX, Wang JW, Youssef M, Cui R, Liang J, Genovese N, et al. LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism. Oncogene. 2017; 36:1245–1255.
12. Liu Y, Murray-Stewart T, Casero RA Jr, Kagiampakis I, Jin L, Zhang J, Wang H, Che Q, Tong H, Ke J, Jiang F, Wang F, Wan X. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. Int J Oncol. 2017; 50:2011–2023.
13. Bernard HU. Regulatory elements in the viral genome. Virology. 2013; 445:197–204.
14. Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog. 2015; 11:e1004712. https://doi.org/10.1371/journal.ppat.1004712.
15. Schneider-Gädicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 1986; 5:2285–2292.
16. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003; 22:5938–5945.
17. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med (Berl). 2007; 85:1253–1262.
18. Persson H, Hennighausen L, Taub R, DeGrado W, Leder P. Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984; 225:687–693.
19. Tao L, Kramer PM, Wang W, Yang S, Lubet RA, Steele VE, Pereira MA. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis. 2002; 23:1447–1454.
20. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, Chen H, Liu XY, Ji H. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 2012; 287:23227–23235.
21. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED, Liu MF. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 2012; 31:1985–1998.
22. Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agrò A, Melino G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013; 32:797–802.
23. Yoshino H, Enokida H, Itesako T, Kojima S, Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M, Seki N. Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci. 2013; 104:1567–1574.
24. Weinstein IB, Joe A, Felsher D. Oncogene addiction. Cancer Res. 2008; 68:3077–3080.
25. Kikuchi Y, Sato S, Sugimura T. Hexokinase isozyme patterns of human uterine tumors. Cancer. 1972; 30:444–447.
26. Pedersen SN. The glycolytic enzyme activity of the human cervix uteri. Cancer. 1975; 35:469–474.
27. Liu Y, Wu K, Shi L, Xiang F, Tao K, Wang G. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis. PLoS One. 2016; 11:e0166230. https://doi.org/10.1371/journal.pone.0166230.
28. Huang X, Liu M, Sun H, Wang F, Xie X, Chen X, Su J, He Y, Dai Y, Wu H, Shen L. HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2015; 8:4054–4063.
29. Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, Yaromina A, Zips D, Walenta S, Baumann M, Mueller-Klieser W. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol. 2010; 94:102–109.
30. Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016; 16:635–649.
31. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24:213–228.
32. Roberts DJ, Tan-Sah VP, Ding EY, Smith JM, Miyamoto S. Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell. 2014; 53:521–533.
33. Nakashima RA, Mangan PS, Colombini M, Pedersen PL. Hexokinase receptor complex in hepatoma mitochondria: evidence from N,Nʹ-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry. 1986; 25:1015–1021.
34. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem. 1988; 263:17422–17428.
35. Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA, Kudryavtseva AV. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets. 2013; 17:1221–1233.
36. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J. 2004; 377:347–355.
37. Majewski N, Nogueira V, Robey RB, Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol. 2004; 24:730–740.
38. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007; 27:7381–7393.
39. Zeng Q, Zhao RX, Chen J, Li Y, Li XD, Liu XL, Zhang WM, Quan CS, Wang YS, Zhai YX, Wang JW, Youssef M, Cui R, et al. O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis. Proc Natl Acad Sci U S A. 2016; 113:9333–9338.
40. Hoppe-Seyler K, Bossler F, Lohrey C, Bulkescher J, Rösl F, Jansen L, Mayer A, Vaupel P, Dürst M, Hoppe-Seyler F. Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. Proc Natl Acad Sci U S A. 2017; 114:E990–E998. https://doi.org/10.1073/pnas.1615758114.
41. Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang M, Chen L, Yang L, Tao Y, Jiang Y, Li J, Yi B, Li B, et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene. 2014; 33:4568–4578.
42. Delgado T, Carroll PA, Punjabi AS, Margineantu D, Hockenbery DM, Lagunoff M. Induction of the Warburg effect by Kaposi’s sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc Natl Acad Sci U S A. 2010; 107:10696–10701.
43. Ramière C, Rodriguez J, Enache LS, Lotteau V, André P, Diaz O. Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol. 2014; 88:3246–3254.
44. Fontaine KA, Sanchez EL, Camarda R, Lagunoff M. Dengue virus induces and requires glycolysis for optimal replication. J Virol. 2015; 89:2358–2366.
45. Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, McCormick F, Graeber TG, Christofk HR. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 2014; 19:694–701.
46. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Discov. 2015; 5:1024–1039.
47. Balló H, Koldovsky P, Hoffmann T, Balz V, Hildebrandt B, Gerharz CD, Bier H. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res. 1999; 19:3827–3836.
48. White JS, Weissfeld JL, Ragin CC, Rossie KM, Martin CL, Shuster M, Ishwad CS, Law JC, Myers EN, Johnson JT, Gollin SM. The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol. 2007; 43:701–712.
49. Leitz J, Reuschenbach M, Lohrey C, Honegger A, Accardi R, Tommasino M, Llano M, von Knebel Doeberitz M, Hoppe-Seyler K, Hoppe-Seyler F. Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog. 2014; 10:e1003957. https://doi.org/10.1371/journal.ppat.1003957.
50. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–408.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.